For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

New Light-Activated Drugs Show Promise in Restoring Vision in Blind Mice

Sep 1, 2026
New Light-Activated Drugs Show Promise in Restoring Vision in Blind Mice

Photoreceptor degeneration is a significant cause of blindness, affecting approximately 200 million people worldwide through conditions such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). These disorders not only impair independence and quality of life but also impose a substantial economic burden, estimated at over $400 billion annually due to healthcare costs and lost productivity. In these diseases, the photoreceptor cells in the retina, responsible for detecting light, gradually deteriorate and die. However, much of the neural circuitry deeper within the retina can remain intact and functional. This presents an opportunity for scientists to explore methods to restore light sensitivity without directly addressing the underlying cause of photoreceptor loss.

A research consortium led by the Institute for Bioengineering of Catalonia (IBEC) has made strides in this area by developing a new class of photoswitchable small-molecule drugs aimed at restoring critical visual functions in animal models of blindness. The findings were published in the Journal of the American Chemical Society (JACS). These compounds are designed to replicate some functions of photoreceptors and can be administered through injection or as eye drops, eliminating the need for genetic modification or invasive procedures. Their promising safety profiles position them as potential candidates for future therapies aimed at restoring vision.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

Pau Gorostiza, an ICREA Research Professor at IBEC and leader of the Nanoprobes and Nanoswitches group, notes that while these molecules do not cure blindness, they are effective at restoring sight through a straightforward and patient-friendly approach. Rosalba Sortino, a postdoctoral researcher at IBEC and co-first author of the study, emphasizes the goal of reactivating retinal processing at the level of the retinal circuit where photoreceptor cells have been lost.

The technique is based on photopharmacology, which allows for the reversible control of a drug's activity using light. The research team created a family of compounds known as prosthe6, which target ON-bipolar neurons. In blinded zebrafish larvae, these compounds successfully restored saccadic eye movements, a reflex indicating visual acuity. Furthermore, in mouse models of AMD and RP, the treatment restored innate light-avoidance behavior, demonstrating that the mice could detect light and use visual information to guide their actions without any prior training.

Notably, the effects of the treatment were observed under normal indoor lighting conditions, suggesting that the drugs can restore functional light perception sufficient for natural behavior. Two compounds, prosthe6-12 and prosthe6-15, showed particularly promising results, effectively restoring visual behaviors following both injection and topical administration.

These compounds work by targeting a protein (mGlu6) within the surviving retinal circuitry, allowing them to substitute for some functions normally provided by photoreceptors. When light reaches the eye, the molecules undergo a shape change, triggering signaling within the retina similar to the normal visual process. The researchers refer to these compounds as "molecular prostheses" because they enable the retina to respond to light without the need for implanted hardware or genetic modification.

Importantly, these drugs can function under ordinary illumination, unlike some optogenetic approaches that require specialized light sources. The prosthe6 technology is currently protected by patent, and researchers are investigating its safety and formulation to extend the duration of restored visual function. They are also collaborating with Eyelumina, a spin-off company, to secure investments for translational development and future clinical trials.

Gorostiza acknowledges that transforming this research into a viable therapy is a lengthy process. However, the results indicate a realistic possibility of restoring high-quality vision with these drugs, offering a non-invasive and reversible mechanism independent of specific retinal disorders or genetic mutations, potentially benefiting a wide range of patients. If successful, this approach could provide an accessible alternative to current vision-restoration technologies, especially for those with advanced retinal degeneration who currently lack effective treatment options. The project received early funding from various sources, including the patients' foundation Fundaluce and the Government of Catalonia.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)